{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:46:50Z","timestamp":1791586010872,"version":"4.3.4"},"reference-count":69,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian Government Research Training Program Scholarship"},{"name":"Hematology Department, Royal North Shore Hospital, Sydney, NSW"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Allogeneic hematopoietic stem cell transplant (allo-HSCT) is an expensive and resource intensive procedure. This study aims to review the literature pertaining to healthcare resource utilization (HRU) and costs associated with allo-HSCT complications. The review followed the Joanna Briggs Institute methodology for scoping reviews. The PubMed, EMBASE, and Health Business Elite were searched in addition to the grey literature. Eligibility criteria included studies that reported HRU and\/or costs associated with adult (\u226518 years) allo-HSCT. Studies were categorized according to complications of allo-HSCT including graft-versus-host disease (acute and chronic GVHD) and infections (fungal, cytomegalovirus, virus-associated hemorrhagic cystitis, and acute respiratory tract infection). Commonly reported HRU and cost measures were extracted, including those associated with the direct management of allo-HSCT complications and intensive care unit (ICU) admissions. Reported costs were standardized to 2022 United States Dollars. Patients who experienced GVHD or infection post-transplant had an overall greater HRU including higher rates of hospitalization, hospital readmission, ICU admission, and longer length of stay compared to those patients who did not. Patients with severe or refractory GVHD and\/or infection following allo-HSCT required greater healthcare intervention. This scoping review synthesizes the current literature on HRU and costs associated with post allo-HSCT complications. Patients who experienced post allo-HSCT complications had higher HRU and incurred higher costs overall, noting the variability across studies in their clinical context, reporting of HRU, and cost measures.<\/jats:p>","DOI":"10.3390\/curroncol32050283","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:24:02Z","timestamp":1747391042000},"page":"283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare Resource Use and Costs of Allogeneic Hematopoietic Stem Cell Transplantation Complications: A Scoping Review"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-7939","authenticated-orcid":false,"given":"Nancy V.","family":"Kim","sequence":"first","affiliation":[{"name":"Centre for Health Economics Research and Evaluation, University of Technology Sydney, Chippendale 2008, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-5678","authenticated-orcid":false,"given":"Gemma","family":"McErlean","sequence":"additional","affiliation":[{"name":"School of Nursing, University of Wollongong, Wollongong 2522, Australia"},{"name":"Ingham Institute for Allied Health Research, Liverpool 2170, Australia"},{"name":"St George Hospital, South Eastern Local Health District, Kogarah 2217, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Yu","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Research and Evaluation, University of Technology Sydney, Chippendale 2008, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kerridge","sequence":"additional","affiliation":[{"name":"Department of Hematology, Royal North Shore Hospital, St Leonards 2065, Australia"},{"name":"Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown 2006, Australia"},{"name":"Northern Blood Research Centre, Kolling Institute, St Leonards 2064, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-2613","authenticated-orcid":false,"given":"Matthew","family":"Greenwood","sequence":"additional","affiliation":[{"name":"Department of Hematology, Royal North Shore Hospital, St Leonards 2065, Australia"},{"name":"Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown 2006, Australia"},{"name":"Northern Blood Research Centre, Kolling Institute, St Leonards 2064, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De Abreu Lourenco","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Research and Evaluation, University of Technology Sydney, Chippendale 2008, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-44241-0","article-title":"The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed\/refractory diffuse large B cell lymphoma","volume":"13","author":"Min","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_2","first-page":"917.e1","article-title":"Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry","volume":"30","author":"Cusatis","year":"2024","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-023-01943-3","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey","volume":"58","author":"Passweg","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1038\/bcj.2011.14","article-title":"Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update","volume":"1","author":"Mohty","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s11764-021-01038-2","article-title":"Long-term treatment burden following allogeneic blood and marrow transplantation in NSW, Australia: A cross-sectional survey","volume":"16","author":"McErlean","year":"2021","journal-title":"J. Cancer Surviv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41409-023-01930-8","article-title":"Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France","volume":"58","author":"Michonneau","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pereira, M.R., Pouch, S.M., and Scully, B. (2018). Infections in Allogeneic Stem Cell Transplantation. Principles and Practice of Transplant Infectious Diseases, Springer.","DOI":"10.1007\/978-1-4939-9034-4_11"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.15515","article-title":"Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis","volume":"19","author":"Torres","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study\u2014Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","first-page":"542.e1","article-title":"Healthcare Resource Utilization and Cost Associated with Allogeneic Hematopoietic Stem Cell Transplantation: A Scoping Review","volume":"30","author":"Kim","year":"2024","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbmt.2009.01.011","article-title":"Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant Complications","volume":"15","author":"Majhail","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1200\/OP.20.00170","article-title":"Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation","volume":"17","author":"Godara","year":"2021","journal-title":"JCO Oncol. Pr."},{"key":"ref_14","first-page":"798.e1","article-title":"Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report","volume":"27","author":"Lindsay","year":"2021","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: Changes over calendar year time, infections and associated factors","volume":"55","author":"Ebmt","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol. Stem Cell Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/bmt.2017.70","article-title":"Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation","volume":"52","author":"Decook","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbmt.2018.12.069","article-title":"Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting","volume":"25","author":"Murthy","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI \u00c9vid. Synth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Munn, Z., Peters, M.D.J., Stern, C., Tufanaru, C., McArthur, A., and Aromataris, E. (2018). Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol., 18.","DOI":"10.1186\/s12874-018-0611-x"},{"key":"ref_22","unstructured":"The World Bank (2022, June 01). World Bank Country and Lending Groups. Available online: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"ref_23","first-page":"1","article-title":"Importance of Nongovernmental Organizations for the Establishment of a Successful Hematopoietic Stem-Cell Transplantation Program in a Developing Country","volume":"4","author":"Franco","year":"2018","journal-title":"J. Glob. Oncol."},{"key":"ref_24","unstructured":"CADTH (2019). Grey Matters: A Practical Tool for Searching Health-Related Grey Literature, Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0049124118799372","article-title":"Interrater Reliability in Systematic Review Methodology: Exploring Variation in Coder Decision-Making","volume":"50","author":"Belur","year":"2021","journal-title":"Sociol. Methods Res."},{"key":"ref_26","unstructured":"Board of Governors of the Federal Reserve System (2023, July 03). Federal Reserve Board: Data Download Program\u2014Home, Available online: https:\/\/www.federalreserve.gov\/datadownload\/."},{"key":"ref_27","unstructured":"Bureau of Labor Statistics Data (2023, July 03). U.S. Bureau of Labor Statistics, Available online: https:\/\/data.bls.gov\/timeseries\/CUUR0000SA0L1E?output_view=pct_12mths."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1182\/blood-2002-03-0984","article-title":"Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: Clinical outcomes, quality of life, and costs","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"ref_29","first-page":"504.e1","article-title":"Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis","volume":"27","author":"Bachier","year":"2021","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","first-page":"707.e1","article-title":"Healthcare Resource Utilization and Costs of Steroid-Associated Complications in Patients With Graft-Versus-Host Disease","volume":"28","author":"Bell","year":"2022","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s41669-021-00264-9","article-title":"Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial","volume":"5","author":"Golan","year":"2021","journal-title":"PharmacoEconomics Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e13233","DOI":"10.1111\/tid.13233","article-title":"Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia","volume":"22","author":"Chen","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"ref_33","first-page":"437","article-title":"Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis","volume":"64","author":"Cornely","year":"2020","journal-title":"Mycoses"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00277-015-2562-1","article-title":"Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: \u201creal life\u201d evaluation","volume":"95","author":"Bertz","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_35","first-page":"505.e1","article-title":"Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States","volume":"27","author":"McGuirk","year":"2021","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/bmt.2013.235","article-title":"High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Gilis","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/13696998.2022.2088184","article-title":"Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: A retrospective claims data analysis","volume":"25","author":"Wattanakamolkul","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.bbmt.2018.11.012","article-title":"Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes","volume":"25","author":"Huang","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","article-title":"Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Yu","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2019.10.028","article-title":"Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients with Acute Graft-versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, following Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Yu","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1007\/s00520-022-06915-9","article-title":"Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: A real-world data study","volume":"30","author":"Sabatelli","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1007.e1","DOI":"10.1016\/j.jtct.2021.09.004","article-title":"Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes","volume":"27","author":"Farhadfar","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40801-022-00320-8","article-title":"Treatment Pathways and Health Outcomes of German Patients with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Health Claims Data Analysis","volume":"9","author":"Scheid","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10198-020-01249-x","article-title":"Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease","volume":"22","author":"Schain","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/jca.21606","article-title":"Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization","volume":"33","author":"Yerrabothala","year":"2017","journal-title":"J. Clin. Apher."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jca.21901","article-title":"Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain","volume":"36","author":"Boluda","year":"2021","journal-title":"J. Clin. Apher."},{"key":"ref_47","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) (2018). CADTH Common Drug Reviews -Letermovir. Pharmacoeconomic Review Report: Letermovir (Prevymis): (Merck Canada Inc.): Indication: For the Prophylaxis of Cytomegalovirus (CMV) Infection in Adult CMV-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant, Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2018 Canadian Agency for Drugs and Technologies in Health."},{"key":"ref_48","unstructured":"National Institute for Health and Care Excellence (NICE) (2019). Single Technology Appraisal: Letermovir Prophylaxis for Cytomegalovirus Disease After Allogeneic Stem Cell Transplant [ID1153], National Institute for Health and Care Excellence (NICE)."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2147\/IDR.S196282","article-title":"Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy","volume":"12","author":"Restelli","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/13696998.2020.1843321","article-title":"Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong","volume":"23","author":"Chan","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/jmv.26462","article-title":"Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective","volume":"93","author":"Alsumali","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.bbmt.2020.06.025","article-title":"Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation","volume":"26","author":"Fang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1002\/jmv.25895","article-title":"Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation","volume":"92","author":"Chevallier","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/03007995.2019.1664827","article-title":"Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant","volume":"36","author":"Schelfhout","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e12961","DOI":"10.1111\/tid.12961","article-title":"The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation","volume":"20","author":"Webb","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbmt.2019.11.005","article-title":"Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy","volume":"26","author":"Saullo","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1080\/03007995.2019.1649379","article-title":"The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan \u2013 a retrospective database study","volume":"35","author":"Ueno","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: A retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"ref_59","first-page":"95","article-title":"Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: A national, matched cohort study in an inpatient setting","volume":"66","author":"Hakimi","year":"2018","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_60","first-page":"86","article-title":"Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients","volume":"92","author":"Ghantoji","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/03007995.2019.1664826","article-title":"Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant","volume":"36","author":"Schelfhout","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e13947","DOI":"10.1111\/tid.13947","article-title":"Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation\u2014A retrospective single-center study","volume":"24","author":"Ranti","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/03007995.2021.1927691","article-title":"Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: A retrospective database study","volume":"37","author":"Ueno","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3111\/13696998.2013.791301","article-title":"Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Arnan","year":"2013","journal-title":"J. Med. Econ."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e13148","DOI":"10.1111\/tid.13148","article-title":"Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant","volume":"21","author":"Walker","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-med-042921-124739","article-title":"Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients","volume":"74","author":"Saullo","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmii.2024.02.005","article-title":"Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan","volume":"57","author":"Huang","year":"2024","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.bbmt.2020.06.007","article-title":"Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"26","author":"Bittencourt","year":"2020","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:09Z","timestamp":1760031249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050283"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050283","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}